Press Releases

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) on 18 April 2018 issued a convertible loan with a total nominal amount of MSEK 26. In total MSEK 14 of the convertible lo...

Annual General Meeting of Oasmia Pharmaceutical AB (publ) held on 25 September 2018

Oasmia Pharmaceutical AB (publ) held its annual general meeting on Tuesday 25 September 2018. The following main resolutions were passed at the meeting. Adoption of balance sheets and profi...

Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European Union

Apealea receives positive CHMP opinion in the European Union for treatment of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer in combination with carb...

Update regarding the Market Authorization Application of Apealea in the European Union

With reference to yesterday’s communicated agenda for this week’s meeting by the Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency (EMA) has informed Oasmia Phar...

Oasmia completes a private placement of new convertible instruments in the amount SEK 35.2 million

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the total amount of SEK 35,200,000 with...

Oasmia Pharmaceutical AB (publ)

Interim report for the period May – July 2018

Notification from Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB hereby issues a notification that the Company’s loan from Nexttobe AB has according to earlier communication been overtaken by a consortium. Due date for the loan is Septemb...

Oasmia Pharmaceutical publishes the Annual Report for 2017/2018

Oasmia Pharmaceutical’s Annual Report for the fiscal year 2017/2018 is now available at the company’s website, www.oasmia.com.   For further information, please con...

NOTICE OF ANNUAL GENERAL MEETING IN OASMIA PHARMACEUTICAL AB

THE SHAREHOLDERS OF OASMIA PHARMACEUTICAL AB ARE HEREBY GIVEN NOTICE OF THE ANNUAL GENERAL MEETING ON TUESDAY 25 SEPTEMBER 2018, AT 14:00 CET, AT THE OFFICES OF THE COMPANY, VALLONGATAN 1, 752 28 UPPS...

Notification from Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB hereby issues a notification that the Company intends to repay its loan to Nexttobe no later than September 30, 2018 according to previously communicated terms for replacement...